Why the study?
Concerns over hypokalemia and hypomagnesemia due to the aging of dialysis patients prompted reconsideration of potassium and magnesium concentrations in dialysate.
Does AYD001 dialysate maintain small molecule clearance and improve post-dialysis electrolyte levels compared to CAB dialysate in chronic hemodialysis patients?
RCT (n=65)
Randomized crossover
Yes
Does AYD001 dialysate maintain small molecule clearance and improve post-dialysis electrolyte levels compared to CAB dialysate in chronic hemodialysis patients?
AYD001 dialysate provides similar small molecule clearance to CAB while better maintaining post-dialysis potassium and magnesium levels, potentially reducing the risk of hypokalemia and hypomagnesemia in hemodialysis patients.
Answers are grounded in this paper and cite their sources.
Supports AYD001 to reduce post-HD hypokalemia and hypomagnesemia risk; extends dialysate options without compromising clearance.
近年,透析患者の高齢化による低Kおよび低Mg血症が懸念されており,透析液のKとMg濃度を再考する時期である.カーボスターⓇ(CAB)の特徴を維持したAYD001を開発した.AYD001はCABと比較し,K濃度を2.5 mEq/L,Mg濃度を1.5 mEq/Lへ変更し,HCO3-濃度を33 mEq/Lへ減じた透析液である.62例の透析患者を対象にAYD001とCABのクロスオーバー比較試験を実施した.主要評価項目の小分子溶質の除去率は2群で有意な差は認めず,AYD001のCABとの類似性が認められた.副次的評価項目の透析後の血清電解質について,事前に規定された基準範囲を満たしている症例数の割合を算出し,群間比較を行った.血清KおよびMg濃度はCAB群に比べAYD001群が有意に高値で推移した.HCO3-濃度はCAB群に比べAYD001群が低値で推移した.重篤な有害事象は両群で認められなかった.AYD001はCABと同等の有効性および安全性を有し,臨床的に意義のある透析液であると考えられた.
No takes yet. Share an insight, caveat, or question.
Abe et al. (2026) conducted an RCT in End-stage kidney disease on hemodialysis (n=65). AYD001 vs. Carbostar dialysate (CAB) was evaluated on Small molecule solute removal rate (Urea nitrogen) (p=NS).
Synapse has enriched 10 related papers. Consider them for comparative context: